(Q37554029)

English

Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis

scientific article published on 25 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1 reference

29 May 2020

1 reference

PubMed publication ID

comparative study

1 reference

PubMed publication ID

systematic review

1 reference

PubMed publication ID

Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

local neoplasm recurrence

1 reference

17 November 2019

prostate neoplasm

1 reference

3 April 2019

physiological sexual dysfunction

1 reference

8 August 2019

1 reference

17 November 2019

systematic review

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Tobias Engel Ayer Botrel

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Otávio Clark

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Rodolfo Borges dos Reis

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Antônio Carlos Lima Pompeo

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Ubirajara Ferreira

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Marcus Vinicius Sadi

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Francisco Flávio Horta Bretas

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

25 January 2014

5 references

Europe PubMed Central

PMC publication ID

21 August 2017

13 March 2019

3 April 2019

8 August 2019

17 November 2019

6 references

Europe PubMed Central

PMC publication ID

21 August 2017

13 March 2019

3 April 2019

8 August 2019

17 November 2019

29 May 2020

14

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

4 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

3 April 2019

Europe PubMed Central

8 August 2019

Europe PubMed Central

17 November 2019

copyright status

0 references

on focus list of Wikimedia project

0 references

Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Intermittent versus continuous androgen deprivation in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Intermittent androgen suppression for rising PSA level after radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Intermittent versus Continuous Androgen Suppression Therapy: Do We Have Consensus Yet?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Emerging cardiometabolic complications of androgen deprivation therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

[EAU guidelines on prostate cancer].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Intermittent versus continuous androgen suppression for prostatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Guideline for the management of clinically localized prostate cancer: 2007 update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Endocrine complications of androgen-deprivation therapy in men with prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Meta-analysis, Simpson's paradox, and the number needed to treat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Treatment of mid- and lower ureteric calculi: extracorporeal shock-wave lithotripsy vs laser ureteroscopy. A comparison of costs, morbidity and effectiveness.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Identifying relevant studies for systematic reviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

23 August 2017

Safety and tolerability of intermittent androgen deprivation therapy: a literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

6 September 2017

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

28 September 2017

Using numerical results from systematic reviews in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

25 June 2018

Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Androgen deprivation for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913526

1 September 2018

Systematic Reviews in Health Care

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-14-9

21 January 2018

Fetoscopic placement of a transurethral stent for intrauterine obstructive uropathy.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-14-9

21 January 2018

Intermittent androgen deprivation--questions remain

1 reference

https://pubmed.ncbi.nlm.nih.gov/24460605

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reply to C. Mary Schooling, Grace Sembajwe and Ilir Agalliu's Letter to the Editor re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke:

1 reference

https://pubmed.ncbi.nlm.nih.gov/24460605

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EAU guidelines on prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24460605

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update

1 reference

https://pubmed.ncbi.nlm.nih.gov/24460605

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24460605

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://pubmed.ncbi.nlm.nih.gov/24460605

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent endocrine therapy for advanced prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24460605

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24460605

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24460605

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2490-14-9

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37554029&oldid=2200528564"